🎉 #Gate xStocks Trading Share# Posting Event Is Ongoing!
📝 Share your trading experience on Gate Square to unlock $1,000 rewards!
🎁 5 top Square creators * $100 Futures Voucher
🎉 Share your post on X – Top 10 posts by views * extra $50
How to Participate:
1️⃣ Follow Gate_Square
2️⃣ Make an original post (at least 20 words) with #Gate xStocks Trading Share#
3️⃣ If you share on Twitter, submit post link here: https://www.gate.com/questionnaire/6854
Note: You may submit the form multiple times. More posts, higher chances to win!
📅 End at: July 9, 16:00 UTC
Show off your trading on Gate Squ
Hang Likang: Currently, there is only one innovative drug project under research.
Jin10 Data July 1st, Anglikon released an announcement regarding abnormal fluctuations in stock trading. The company has noticed that the market's attention on innovative drug business has been relatively high recently. Currently, the company has only one innovative drug project under research, which is the ALK-N001 project. This project received a notice of approval for clinical trials in April 2025, and as of the date of this announcement, it is still in the Phase I clinical trial stage. The development of innovative drugs is characterized by long cycles, high investment, and high uncertainty, and investors are advised to pay attention to investment risks.